TAMPA, Fla., March 24, 2011 /PRNewswire/ -- Scotia Vision LLC, a global life science consulting partner to pharmaceutical, drug delivery and device companies, announced Monday that it has entered into a definitive merger agreement with i2eye Consulting LLC, a US based firm and provider of commercialization solutions to established and developing ophthalmic companies.
The merger with i2eye Consulting further strengthens Scotia Vision's business model which focuses on ophthalmic product development and market leadership by creating best-in-class practices and offerings that help clients achieve their strategic and operational objectives.
Michael O'Rourke and Susan Benton, ophthalmic industry veterans with 30 years combined experience, who were founders and managing partners of Scotia Vision and i2eye respectively, will be equal partners in the new combined entity. The new company will continue to operate under the Scotia Vision name.
Prior to establishing Scotia Vision Consultants, Michael was General Manager for Bausch+Lomb's US Pharmaceutical division. With extensive global life science experience, Michael has managed teams and multiple leading ophthalmic brands across North America, Europe and Asia, successfully led major product launches including unique drug delivery technologies, negotiated strategic business deals, and has been a team member in a wide portfolio of medical device and drug approvals.
Before i2eye Consulting, Susan Benton was co-founder and SVP of Commercial Operations for Sirion Therapeutics, Inc., an ophthalmic biopharmaceutical company that brought Durezol® and Zirgan® to market. Susan also worked for B+L as the head of pharmaceutical sales and commercial operations where she launched their first branded pharmaceutical products including Lotemax® and Alrex®.
"This transaction reinforces current strengths of Scotia Vision and the strategy to create a world class ophthalmic practice," said O'Rourke. "Merging makes a great deal of sense. Our combined consulting practice provides a scalable alternative to Tier 1 corporate service companies which usually pursue larger multi-service opportunities," added Benton.
The company will be exhibiting at the upcoming eye care meeting, Association for Research in Vision and Ophthalmology (ARVO) in Ft. Lauderdale, FL from May 1-5, 2011 and invite you to stop by booth #122 to meet the team.
About Scotia Vision
Scotia Vision, founded in 2009, is a privately held life sciences consulting practice with an ophthalmic focus based in Tampa, FL. Scotia Vision offers a full range of services that includes strategic planning to program implementation. The company's client list is extensive and includes both US and foreign based companies looking to commercialize their products in the US and abroad. For more information, visit www.scotiavisionllc.com.
Alrex, Lotemax, are registered trademarks of Bausch + Lomb. Zirgan is a registered trademark of Laboratoires Thea. Durezol is a registered trademark of Alcon Inc.
SOURCE Scotia Vision LLC